Refine
Has Fulltext
- yes (9)
Is part of the Bibliography
- yes (9)
Document Type
- Journal article (9)
Language
- English (9) (remove)
Keywords
- CXCR4 (3)
- PET (3)
- theranostics (3)
- 18F-FDG PET/CT (2)
- PRRT (2)
- multiple myeloma (2)
- sarcoidosis (2)
- somatostatin receptor (2)
- 11C-Methionine PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- DOTATOC (1)
- NEC (1)
- NET (1)
- Positronen-Emissions-Tomografie (1)
- SSTR (1)
- [68Ga]Pentixafor (1)
- chemokine receptor (1)
- fibroblast activation protein (1)
- head and neck cancer (1)
- medicine (1)
- molecular imaging (1)
- neuroendocrine tumor (1)
- pattern (1)
- peptide receptor (1)
- peptide receptor radionuclide therapy (1)
- progression (1)
- radiogenomics (1)
- radionuclide therapy (1)
- relapse (1)
- smoldering myeloma (1)
- solid tumors (1)
- somatostatin receptors (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (9)
- Medizinische Klinik und Poliklinik II (4)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
- Medizinische Klinik und Poliklinik I (2)
- Pathologisches Institut (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Comprehensive Cancer Center Mainfranken (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (1)
We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer \(^{68}\)Ga-Pentixafor in patients with poorly differentiated neuroendocrine carcinomas (NEC), relative to the established reference standard \(^{18}\)F-FDG PET/computed tomography (CT). In our database, we retrospectively identified 11 treatment-naïve patients with histologically proven NEC, who underwent \(^{18}\)F-FDG and CXCR4-directed PET/CT for staging and therapy planning. The images were analyzed on a per-patient and per-lesion basis and compared to immunohistochemical staining (IHC) of CXCR4 from PET-guided biopsies. \(^{68}\)Ga-Pentixafor visualized tumor lesions in 10/11 subjects, while \(^{18}\)F-FDG revealed sites of disease in all 11 patients. Although weak to moderate CXCR4 expression could be corroborated by IHC in 10/11 cases, \(^{18}\)F-FDG PET/CT detected significantly more tumor lesions (102 vs. 42; total lesions, n = 107; p < 0.001). Semi-quantitative analysis revealed markedly higher 18F-FDG uptake as compared to \(^{68}\)Ga-Pentixafor (maximum and mean standardized uptake values (SUV) and tumor-to-background ratios (TBR) of cancerous lesions, SUVmax: 12.8 ± 9.8 vs. 5.2 ± 3.7; SUVmean: 7.4 ± 5.4 vs. 3.1 ± 3.2, p < 0.001; and, TBR 7.2 ± 7.9 vs. 3.4 ± 3.0, p < 0.001). Non-invasive imaging of CXCR4 expression in NEC is inferior to the reference standard \(^{18}\)F-FDG PET/CT.